ArticleJournal of neurochemistry2010
Involvement of ERK2 in traumatic spinal cord injury.
Article in Journal of neurochemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Injection of Cerium Oxide Nanoparticles to Treat Spinal Cord Injury in Rats.Journal of neuropathology and experimental neurology · 2022Article
- The role of Wnt/mTOR signaling in spinal cord injury.Journal of clinical orthopaedics and trauma · 2022Review
- Bazedoxifene, a Selective Estrogen Receptor Modulator, Promotes Functional Recovery in a Spinal Cord Injury Rat Model.International journal of molecular sciences · 2021Article
- Calpastatin Overexpression Protects against Excitotoxic Hippocampal Injury and Traumatic Spinal Cord Injury.Journal of neurotrauma · 2020Article
- CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.Molecular neurobiology · 2020Review
- Strategies for Oligodendrocyte and Myelin Repair in Traumatic CNS Injury.Frontiers in cellular neuroscience · 2020Review
- Prospects of siRNA cocktails as tools for modifying multiple gene targets in the injured spinal cord.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- Bisperoxovanadium Mediates Neuronal Protection through Inhibition of PTEN and Activation of PI3K/AKT-mTOR Signaling after Traumatic Spinal Injuries.Journal of neurotrauma · 2019Article
- Repositioning Flubendazole for Spinal Cord Injury.Journal of neurotrauma · 2019Article
- Fire Needle Acupuncture Regulates Wnt/ERK Multiple Pathways to Promote Neural Stem Cells to Differentiate into Neurons in Rats with Spinal Cord Injury.CNS & neurological disorders drug targets · 2019Article
- Beneficial Effects of Resveratrol-Mediated Inhibition of the mTOR Pathway in Spinal Cord Injury.Neural plasticity · 2018Review
- Targeted siRNA delivery reduces nitric oxide mediated cell death after spinal cord injury.Journal of nanobiotechnology · 2017Article
- Xingshentongqiao decoction mediates proliferation, apoptosis, orexin-A receptor and orexin-B receptor messenger ribonucleic acid expression and represses mitogen-activated protein kinase signaling.Chinese medical journal · 2015Article
- Changes in NG2 cells and oligodendrocytes in a new model of intraspinal hemorrhage.Experimental neurology · 2014Article
- Fenbendazole improves pathological and functional recovery following traumatic spinal cord injury.Neuroscience · 2014Article
- Diffuse axonal injury in brain trauma: insights from alterations in neurofilaments.Frontiers in cellular neuroscience · 2014Review
- PTEN/PI3K and MAPK signaling in protection and pathology following CNS injuries.Frontiers in biology · 2013Article
- Calpain 1 knockdown improves tissue sparing and functional outcomes after spinal cord injury in rats.Journal of neurotrauma · 2013Article
- Albumin causes increased myosin light chain kinase expression in astrocytes via p38 mitogen-activated protein kinase.Journal of neuroscience research · 2011Article
- Ras family small GTPase-mediated neuroprotective signaling in stroke.Central nervous system agents in medicinal chemistry · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Activation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) are implicated in the pathophysiology of spinal cord injury (SCI). However, the specific functions of individual ERK isoforms in neurodegeneration are largely unknown. We investigated the hypothesis that ERK2 activation may contribute to pathological and functional deficits following SCI and that ERK2 knockdown using RNA interference may provide a novel therapeutic strategy for SCI. Lentiviral ERK2 shRNA and siRNA were utilized to knockdown ERK2 expression in the spinal cord following SCI. Pre-injury intrathecal administration of ERK2 siRNA significantly reduced excitotoxic injury-induced activation of ERK2 (p < 0.001) and caspase 3 (p < 0.01) in spinal cord. Intraspinal administration of lentiviral ERK2 shRNA significantly reduced ERK2 expression in the spinal cord (p < 0.05), but did not alter ERK1 expression. Administration of the lentiviral ERK2 shRNA vector 1 week prior to severe spinal cord contusion injury resulted in a significant improvement in locomotor function (p < 0.05), total tissue sparing (p < 0.05), white matter sparing (p < 0.05), and gray matter sparing (p < 0.05) 6 weeks following severe contusive SCI. Our results suggest that ERK2 signaling is a novel target associated with the deleterious consequences of spinal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.